The developer and manufacturer of dotalizumab (Jemperli)

Dotalizumab (Jemperli) was developed by the drug manufacturing company Tesaro Inc., which was later acquired by GlaxoSmithKline (GSK). The drug was developed by Tesaro as part of its ongoing cancer research and development efforts to improve treatment options and survival for patients with ovarian cancer.

Tesaro Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts, USA. The company focuses on developing innovative cancer treatments, particularly in the area of u200bu200bgynecological cancers such as ovarian cancer. Dotalizumab is an important result of Tesaro's research and development, providing a new treatment option for ovarian cancer patients.

The research and development process of dotalizumab involved a large number of clinical trials and research work. The goal of these research efforts is to verify the drug's effectiveness and safety to ensure patients can benefit from this new treatment. In clinical trials, dotalizumab has shown significant efficacy in patients with ovarian cancer, particularly those with highly unstable microsatellite mismatch (dMMR) or deficient DNA mismatch repair (dMMR) signatures.

In short, the manufacturer of dotalizumab (Jemperli) isTesaro Inc., which, following its merger with GlaxoSmithKline (GSK), will continue to advance the research and development of this important cancer treatment to improve survival and quality of life for patients with ovarian cancer. The development of this drug represents the pharmaceutical industry's ongoing efforts to provide better treatment options for cancer patients.

Dotalizumab is not currently on the market in China, and it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.